pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
GILEAD · news · pharmadog
← back to GILEAD
News mentioning GILEAD
190
stories
2d
Gilead CAR-T on partial clinical hold; Agios' PDUFA date pushed back
endpoints
2d
Immutep, Molecular cut workforces
biospace
3d
AstraZeneca cuts early-phase prostate cancer pipeline
fiercebiotech
3d
Gilead reveals partial clinical hold on 2 CAR-T cell therapy trials
fiercebiotech
3d
STAT+: Vertex kidney disease drug scrutinized for infection risk
stat
4d
Biopharma cuts at manufacturing plants expected to affect 4,000+
biospace
5d
Astellas makes $1.3B bet on Audax’s preclinical push to reverse decades of IL-12 woes
fiercebiotech
5d
5 new drug launches that defied industry expectations
biospace
6d
Parkinson’s-focused Aspen and bispecific biotech Bambusa both shoot for $134M IPOs
fiercebiotech
6d
STAT+: House lawmaker probes PBMs for ‘punitive’ audits of independent pharmacies
stat
6d
Another autoimmune CAR-T death; Treasury zeroes in on China deals
biopharma dive
6d
STAT+: Pharmalittle: We’re reading about a Roche lung cancer drug, a Bristol CAR-T trial death, and more
stat
9d
STAT+: Most cancer drugs approved by European regulators lack a high clinical benefit, analysis finds
stat
9d
STAT+: Up and down the ladder: The latest comings and goings
stat
9d
Gilead shops in IL-23, inking $1.3B upfront I&I deal with China’s PepStar
biospace
9d
ESMO 2026: Marengo's bispecific antibody shrinks 8 tumor types in Phase 2
biospace
9d
STAT+: Pharmalittle: We’re reading about a cancer vaccine, an experimental pancreatic cancer drug, and more
stat
10d
Gilead to pay $1.3B upfront for PepStar’s oral IL-23 challenger to J&J’s Icotyde
fiercebiotech
10d
Gilead strikes $1.3B upfront China deal for oral IL-23 drug
endpoints
10d
STAT+: Gilead to pay $45 million to settle kickback charges filed by Texas attorney general
stat
10d
GSK, Ionis hepatitis B functional cure breaks open market for followers
biospace
10d
STAT+: Pharmalittle: We’re reading about a U.S. rule on Chinese deals, Belgium refusing Mounjaro coverage, and more
stat
10d
STAT+: What to expect from the Moderna-Merck cancer vaccine data reveal
stat
11d
ESMO 2026: Merck’s Kelun-partnered ADC hits the ‘Goldilocks zone,’ VP says
biospace
11d
STAT+: Pharmalittle: We’re reading about Mark Cuban eyeing rare disease drugs, a ketamine gold rush, and more
stat
12d
The 6 biggest crossover rounds in biopharma history
biospace
12d
STAT+: Roche continues to look to China for new drugs
stat
12d
Why I wish you didn’t want to see Nathan Fielder’s Elizabeth Holmes documentary
stat
12d
STAT+: OpenEvidence’s JAMA paper leaves open questions
stat
12d
STAT+: Pharmalittle: We’re reading about drug launch prices, an AstraZeneca AI deal, and more
stat
← prev
page 1 of 7
next →
